Cogent Biosciences, Inc.
COGT
Rangering i aksjer
#3254
Cogent Biosciences, Inc. is a biotechnology firm dedicated to creating targeted... Cogent Biosciences, Inc. is a biotechnology firm dedicated to creating targeted treatments for illnesses rooted in specific genetic anomalies. The company's primary therapeutic candidate is CGT9486, a selective tyrosine kinase inhibitor engineered to block the KIT D816V mutation, a key driver of systemic mastocytosis, along with other KIT exon 17 mutations observed in individuals suffering from advanced gastrointestinal stromal tumors (GIST). Furthermore, Cogent holds a licensing pact with Plexxikon Inc., granting it rights for the investigation, advancement, and marketing of bezuclastinib. Previously known as Unum Therapeutics Inc., the company adopted its current name, Cogent Biosciences, Inc., in October 2020. Established in 2014, Cogent Biosciences is headquartered in Cambridge, Massachusetts.
Aksjekurs
$31.37
Markedsverdi
$5.44B
Endring (1 dag)
4.54%
Endring (1 år)
93.42%
Land
US
Handel Cogent Biosciences, Inc. (COGT)
Kategori
Healthcare
P/S-forhold for Cogent Biosciences, Inc. (COGT)
P/S-forhold per October 2026 TTM: 0.00
Ifølge Cogent Biosciences, Inc. sine siste finansielle rapporter og aksjekurs er selskapets nåværende P/S-forhold (TTM) 0.00. Ved slutten av 2023 hadde selskapet et P/S-forhold på 0.00.
P/S-historikk for Cogent Biosciences, Inc. fra 2015 til 2026
P/S-forhold ved hvert års slutt
| År | P/S-forhold | Endre |
|---|---|---|
| 2026 (TTM) | 0.00 | 0.00% |
| 2024 | 0.00 | 0.00% |
| 2023 | 0.00 | 0.00% |
| 2022 | 0.00 | 0.00% |
| 2021 | 0.00 | -100.00% |
| 2020 | 15.81 | 1,520.90% |
| 2019 | 0.98 | -91.33% |
| 2018 | 11.25 | -71.38% |
| 2017 | 39.32 | -3.98% |
| 2016 | 40.95 | -53.01% |
| 2015 | 87.14 | 0.00% |
P/S-forhold for lignende selskaper eller konkurrenter
| Selskap | P/S-forhold | Forskjell i P/S-forhold | Land |
|---|---|---|---|
| 10.02 | - |
US
|
|
| 40.55 | - |
US
|
|
| 3.96 | - |
AU
|
|
| - | - |
CH
|
|
| 10.15 | - |
NL
|
